Q3 2019 13F Holders as of 9/30/2019
-
Type / Class
-
Equity / COM
-
Number of holders
-
39
-
Total 13F shares, excl. options
-
19.4M
-
Shares change
-
+50.6K
-
Total reported value, excl. options
-
$80.6M
-
Value change
-
+$347K
-
Put/Call ratio
-
0.78
-
Number of buys
-
16
-
Number of sells
-
-16
-
Price
-
$4.16
Significant Holders of AVADEL PHARMACEUTICALS - COM (AVDL) as of Q3 2019
53 filings reported holding AVDL - AVADEL PHARMACEUTICALS - COM as of Q3 2019.
AVADEL PHARMACEUTICALS - COM (AVDL) has 39 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 19.4M shares
.
Largest 10 shareholders include BRANDES INVESTMENT PARTNERS, LP (6.18M shares), Broadfin Capital, LLC (3.1M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (2.72M shares), BROWN CAPITAL MANAGEMENT LLC (1.7M shares), RENAISSANCE TECHNOLOGIES LLC (822K shares), Tekla Capital Management LLC (815K shares), AMERIPRISE FINANCIAL INC (765K shares), MORGAN STANLEY (740K shares), DEUTSCHE BANK AG\ (588K shares), and JW Asset Management, LLC (444K shares).
This table shows the top 39 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.